The magnitude and the long-term clinical impact of these effects is still being evaluated, but the data available suggest GLP-1 RAs (and likely SGLT2 inhibitors) play a main role in the treatment of NAFLD. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.